Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain

Current Medical Research and Opinion

Volumn 22, Issue 8, 2006, Pages 1503-1514

  Nicholson, Bruce ^a   Ross, Edgar ^b   Sasaki, John ^c   Weil, Arnold ^d  

^a Pain Specialists of Greater Lehigh Valley   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Casa Colina Centers for Rehabilitation   (United States)

^d Non Surgical Orthopaedic and Spine Center   (United States)

Author keywords

Chronic pain; Kadian; Long term analgesia; Nonmalignant pain; Opioid; Orphine; Oxycodone; OxyContin

Indexed keywords

MORPHINE SULFATE; OXYCODONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PATIENT ASSESSMENT; PERIPHERAL EDEMA; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANALGESICS, OPIOID; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; OXYCODONE; PAIN; PAIN CLINICS; PAIN MEASUREMENT; POLYMERS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33748036026     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X115603     Document Type: Article

References (57)

1. Nagda J, Bajwa ZH. Definitions and classification of pain. In: Warfield CA, Bajwa ZH, editors. Principles and practice of pain medicine, 2nd ed. New York: McGraw-Hill; 2004
2. American Pain Society. Pain: current understanding of assessment, management and treatments, 2005. Available at: http://www.ampainsoc.org/ce/npc/ I/a_introduction.htm [accessed 10 June 2005]
3. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003;63:17-32
4. AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc 2002;50(Suppl 6):S205-S224
5. American Society of Anesthesiologists, Inc. Practice guidelines for chronic pain management: a report by the American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section. Anesthesiology 1997;86:995-1004
6. Marcus DA. Treatment of nonmalignant chronic pain. Am Fam Physician 2000;61:1331-8, 1345-6
7. Fields HL, Martin JB. Pain: pathophysiology and management. In: Braunwald E, Fauci AS, Kasper DL, et al, editors. Harrison's principles of internal medicine, 15th ed. New York: McGraw-Hill; 2001. p.55-60
8. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. J Am Med Assoc 2005;293:3043-52
9. Katz N, Benoit C. Opioids for neuropathic pain. Curr Pain Headache Rep 2005;9:153-60
10. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002;59:1015-21
11. American Pain Society. The use of opioids for the treatment of chronic pain: a consensus statement from American Academy of Pain Medicine and American Pain Society, 2005. Available at: http://www.ampainsoc.org/advocacy/opioids.htm [accessed 10 June 2005]
12. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001;8:181-6
13. Verispan LLC. Vector One™: National (VONA). Twelve-month period ending August 2005
14. KADIAN [package insert] : Alpharma Branded Products Division Inc., Piscataway (NJ); 2004
15. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain, 5th ed. Glenview (IL): American Pain Society; 2003
16. Broomhead A, West R, Eglinton L, et al. Comparative single-dose pharmacokinetics of sustained-release and modified-release morphine sulfate capsules under fed and fasting conditions. Clin Drug Invest 1997;13:162-70
17. Maccarrone C, West RJ, Broomhead AF, Hodsman GP. Single dose pharmacokinetics of Kapanol™, a new oral sustained-release morphine formulation. Drug Invest 1994;7:262-74
18. Gourlay GK, Cherry DA, Onley MM, et al. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain 1997;69:295-302
19. Nicholson B, Ross E, Weil A, et al. Treatment of chronic moderate-to-severe nonmalignant pain with polymer-coated extended-release morphine sulfate capsules. Curr Med Res Opin 2006;22:539-50
20. Chao J. Retrospective analysis of Kadian® (morphine sulfate sustained-release capsules) in patients with chronic, non-malignant pain. Pain Med 2005;6:262-5
21. OxyContin [package insert]: Purdue Pharma L.P., Stamford (CT); 2004
22. Adams D, Gunyea I, Bhakta B, et al. Retrospective assessment of frequency of dosing of sustained release opiate preparations in chronic pain patients. Pain Med 2002;3:185 [abstract]
23. Ackerman SJ, Mordin M, Reblando J, et al. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm 2003;9:223-31
24. Marcus DS, Glick RM. Sustained-release oxycodone dosing survey of chronic pain patients. Clin J Pain 2004;20:363-6
25. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000;160:853-60
26. International Conference on Harmonisation. Guidance tor industry. Good clinical practice: consolidated guidance (ICH-E6). Rockville (MD): Center tor Drug Evaluation and Research (CDER); 1997
27. US Food and Drug Administration. Code of federal regulations, title 21, 2004. Available at: http://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?CFRPart=50 [accessed 10 August 2005]
28. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Available at: http://www.wma.net/e/policy/pdf/17c.pdf [accessed 10 August 2005]
29. Ware Jr JE, Kosinski M, Dewey JE. How to score version 2 of the SF-36® Health Survey. Lincoln (RI): QualityMetric Incorporated, 2000
30. Cleeland CS. Brief pain inventory (short form). 1991. Available at: http://www.mdanderson.org/pdf/bpilong.pdf [accessed 10 May 2005]
31. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the brief pain inventory for chronic nonmalignant pain. J Pain 2004;5:133-7
32. Keller S, Bann CM, Dodd SL, et al. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004;20:309-18
33. Farrar JT, Young Jr JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
34. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628-38
35. Freynhagen R, von Giesen HJ, Busche P, et al. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage 2005;30:289-97
36. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92
37. McCracken LM, Iverson GL. Disrupted sleep patterns and daily functioning in patients with chronic pain. Pain Res Manag 2002;7:75-9
38. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999;26:862-9
39. Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic-back pain. Clin J Pain 1999;15:179-83
40. Markenson JA, Croft J, Zhang PG, et al. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005;21:524-35
41. Heiskanen T, Kalso K. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997;73:37-45
42. Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J 2004;97:129-34
43. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 2003;26:1026-48
44. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review oi eificacy and safety. Pain 2004;112:372-80
45. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
46. Drewes AM. Pain and sleep disturbances with special reference to fibromyalgia and rheumatoid arthritis. Rheumatology (Oxford) 1999;38:1035-8
47. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 2000;909:186-216
48. Kreek MJ, Borg E, Zhou Y, Schluger J. Relationships between endocrine functions and substance abuse syndromes: heroin and related short-acting opiates in addiction contrasted with methadone and other long-acting opioid agonists used in pharmacotherapy of addiction. In: Pfaff D, Arnold A, Etgen A, et al., editors. Hormones, brain and behavior. New York: Academic Press; 2002
49. Emanuel FJ, Miller FG. The ethics of placebo-controlled trials - a middle ground. New Engl J Med 2001;345:915-9
50. Sullivan M, Terman GW, Peck B, et al. APS position statement on the use of placebos in pain management. J Pain 2005;6:215-7
51. Swartzman EC, Burkell J. Expectations and the placebo effect in clinical drug trials: why we should not turn a blind eye to unblinding, and other cautionary notes. Clin Pharmacol Ther 1998;64:1-7
52. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1992;1:113-9
53. Fillingim RB, Gear RW. Sex differences in opioid analgesia: clinical and experimental findings. Eur J Pain 2004;8:413-25
54. Cepeda MS, Carr DB. Women experience more pain and require more morphine than men to achieve a similar degree of analgesia. Anesth Analg 2003;97:1464-8
55. Fillingim RB, Ness TJ, Glover TE, et al. Morphine responses and experimental pain: sex differences in side effects and cardiovascular responses but not analgesia. J Pain 2005;6:116-24
56. Sarton E, Olofsen E, Romberg R, et al. Sex differences in morphine analgesia: an experimental study in healthy volunteers. Anesthesiology 2000;93:1245-54
57. Craft RM. Sex differences in opioid analgesia: 'from mouse to man'. Clin J Pain 2003;19:175-86